Safety data and beneficial effects of the combined oral contraceptive ethinylestradiol 0.03 mg/Chlormadinone acetate 2mg (Belara®): A 13-cycle, observational study in routine clinical practice

Clinical Drug Investigation

Volumn 31, Issue 2, 2011, Pages 121-134

  Pushparajah, Daphnee S ^a   Röhm, Petra ^a   Hschen, Kornelia ^a   Albers, Dagmar ^a   Nowack, Christina ^a  

^a GRÜNENTHAL GMBH   (Germany)

Author keywords

Chlormadinone, therapeutic use; Contraception; Ethinylestradiol, therapeutic use; Ethinylestradiolchlormadinone, therapeutic use; Oral contraceptives, therapeutic use

Indexed keywords

CHLORMADINONE ACETATE PLUS ETHINYLESTRADIOL; ORAL CONTRACEPTIVE AGENT;

ACNE; ADULT; ADVERSE OUTCOME; ARTICLE; BODY MASS; BODY WEIGHT; BREAKTHROUGH BLEEDING; CHOLELITHIASIS; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSMENORRHEA; FEMALE; HEADACHE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MASTALGIA; MENSTRUAL CYCLE; PRIORITY JOURNAL; SPOTTING; THERAPY EFFECT; THROMBOSIS; VITAL SIGN; WELLBEING;

ACNE VULGARIS; ADULT; CHLORMADINONE ACETATE; CONTRACEPTIVES, ORAL, COMBINED; DYSMENORRHEA; ETHINYL ESTRADIOL; FEMALE; HUMANS; MENSTRUAL CYCLE; PATIENT SATISFACTION; TREATMENT OUTCOME;

EID: 78650301961     PISSN: 11732563     EISSN: 11791918     Source Type: Journal    
DOI: 10.2165/11585900-000000000-00000     Document Type: Article

References (44)

1. Plewig G, Cunliffe WJ, Binder N, et al. Efficacy of an oral contraceptive containing EE 0.03 mg and CMA 2mg (Belara-) in moderate acne resolution: a randomized, double-blind, placebo-controlled phase III trial. Contraception 2009; 80 (1): 25-33
2. Kerscher M, Reuther T, Bayrhammer J, et al. Effects of an oral contraceptive containing chlormadinone and ethinylestradiol on acne-prone skin of women of different age groups: an open-label, single-centre, phase IV study. Clin Drug Investig 2008; 28 (11): 703-11
3. Schramm G, Steffens D. Contraceptive efficacy and tolerability on chlormadinone acetate 2mg/ethinyl estradiol 0.03 mg (Belara-): results of a post-marketing surveillance trial. Clin Drug Invest 2002; 22 (4): 221-31
4. Schramm G, Steffens D. A 12-month evaluation of the CMA-containing oral contraceptive Belara-: efficacy, tolerability and anti-androgenic properties. Contraception 2003; 67 (4): 305-12
5. Schramm G, Heckes B. Switching hormonal contraceptives to a chlormadinone acetate-containing oral contraceptive. The Contraceptive Switch Study. Contraception 2007; 76 (2): 84-90
6. Mall-Haefeli M. Die Wirkung der Androgene auf das Zyklusgeschehen. In: Loch EG, Schramm G, editors. Chlormadinonacetat bei Androgenisierungserscheinungen. Stuttgart: Schattauer, 1995: 42-55
7. Kaiser E. Action of a new hormonal contraceptive (Neo- Eunomin-) on androgenisation of the skin in women. Geburtshilfe Frauenheilkd 1984; 44: 651-5
8. Carlborg L. Cyproterone acetate versus levonorgestrel combined with ethinyl estradiol in the treatment of acne. Acta Obstet Gynecol Scand 1986; 134 Suppl.: 29-32 (Pubitemid 17190174)
9. Breckwoldt M, Zahradnik HP, Wiecker P. Hirsutismus. In: Orfanos CE, Happle R, editors. Hair and hair diseases. Berlin: Springer, 1990: 777-89
10. Luderschmidt C. Akne der Frau: eine interdisziplinaüre Herausforderung. In: Loch EG, Schramm G, editors. Chlormadinonacetat bei Androgenisierungserscheinungen. Stuttgart: Schattauer, 1995: 57-76
11. Kuhl H. Comparative pharmacology of newer progestogens. Drugs 1996; 51 (2): 188-215 (Pubitemid 26039155)
12. Rabe T, Kowald A, Ortmann J, et al. Inhibition of skin 5 alpha-reductase by oral contraceptive progestins in vitro. Gynecol Endocrinol 2000; 14 (4): 223-30
13. Worret I, Arp W, Zahradnik HP, et al. Acne resolution rates: results of a single-blind, randomized, controlled, parallel phase III trials with EE/CMA (Belara-), EE/LNG (Microgynon). Dermatology 2001; 203 (1): 38-44
14. Raudrant D, Rabe T. Progestogens with antiandrogenic properties. Drugs 2003; 63 (5): 463-92 (Pubitemid 36337727)
15. Druckmann R. Profile of the progesterone derivative chlormadinone acetate: pharmacodynamic properties and therapeutic applications. Contraception 2009; 79(4): 272-81
16. Gerstmann BB, Piper JM, Tomita DK, et al. Oral contraceptive estrogen dose and the risk of deep venous thromboembolic disease. Am J Epidemiol 1991; 133 (1): 32-7
17. Kuhl H. Chemie und Pharmakologie von Chlormadinonacetat. In: Loch EG, Schramm G, editors. Chlormadinonacetat bei Androgenisierungserscheinungen. Stuttgart: Schattauer, 1995: 1-12
18. Rosenberg MJ, Waugh MS. Oral contraceptive discontinuation: a prospective evaluation of frequency and reasons. Am J Obstet Gynecol 1998; 179: 577-82
19. Akerlund M, Rode A, Westergaard J. Comparative profiles of reliability: cycle control and side effects of two oral contraceptive formulations containing 150 micrograms desogestrel and either 30 micrograms or 20 micrograms ethinyl oestradiol. Br J Obstet Gynaecol 1993; 100 (9): 832-8 (Pubitemid 23280566)
20. Parsey KS, Pong A. An open-label, multicenter study to evaluate Yasmin, a low-dose combination oral contraceptive containing drospirenone, a new progestogen. Contraception 2000; 61 (2): 105-11 (Pubitemid 30236331)
21. Zahradnik HP, Hanjalic-Beck A. Efficacy, safety and sustainability of treatment continuation and results of an oral contraceptive containing 30mcg ethinyl estradiol and 2mg chlormadinone acetate, in long-term usage (up to 45 cycles): an open-label, prospective, noncontrolled, office-based phase III study. Contraception 2008; 77 (5): 337-43
22. Winkler UH, Sudik R. The effects of two monophasic oral contraceptives containing 30mcg of ethinyl estradiol and either 2mg of chlormadinone acetate or 0.15 mg of desogestrel on lipid, hormone and metabolic parameters. Contraception 2009; 79 (1): 15-23
23. Sachs L. Angewandte Statistik: Statistische Methoden und ihre Anwendung. Berlin, Heidelberg, New York: Springer, 1978
24. Gerlinger C, Endrikat J, van der Meulen EA, et al. Recommendation for confidence interval and sample size calculation for the Pearl Index. Eur J Contracept ReprodHealth Care 2003; 8 (2): 87-92 (Pubitemid 36791750)
25. Fotherby K. Twelve years of clinical experience with an oral contraceptive containing 30 micrograms ethinyloestradiol and 150 micrograms desogestrel. Contraception 1995; 51 (1): 3-12
26. Endrikat J, Muüller U, Duüsterberg B. A twelve-month comparative clinical investigation of two low dose oral contraceptives containing 20 micrograms ethinyl estradiol/75 micrograms gestodene and 30 micrograms ethinyl estradiol/ 75 micrograms gestodene, with respect to efficacy, cycle control, and tolerance. Contraception 1997; 55 (3): 131-7 (Pubitemid 27180387)
27. Foidart JM, Wuttke W, Bouw GM, et al. A comparative investigation of contraceptive reliability, cycle control and tolerance of two monophasic oral contraceptives containing either drospirenone or desogestrel. Eur J Contracept Reprod Health Care 2000 Jun; 5 (2): 124-34 (Pubitemid 30470064)
28. Gollnick H, Albring M, Brill K. The efficacy of oral cyproterone acetate in combination with ethinyloestradiol in acne tarda of the facial type. Ann Endocrinol (Paris) 1999 Sep; 60 (3): 157-66 (Pubitemid 29448991)
29. Huber J, Foidart JM, Wuttke W, et al. Efficacy and tolerability of a monophasic oral contraceptive containing ethinyl estradiol and drospirenone. Eur J Contracept Reprod Health Care 2000; 5 (1): 25-34 (Pubitemid 30321317)
30. Akerlund M. Clinical experience of a combined oral contraceptive with very low dose ethinyl estradiol. Acta Obstet Gynecol Scand Suppl. 1997; 164: 63-5 (Pubitemid 27302779)
31. Vartiainen M, de Gezelle H, Broekmeulen CJ. Comparison of the effect on acne with a combiphasic desogestrel-containing oral contraceptive and a preparation containing cyproterone acetate. Eur J Contracept ReprodHealth Care 2001; 6 (1): 46-53 (Pubitemid 32375012)
32. Gallo MF, Lopez LM, Grimes DA, et al. Combination contraceptives: effects on weight (review). Cochrane Database Syst Rev 2006; (2): 1-72
33. Rosenberg MJ, Long SC. Oral contraceptives and cycle control: a critical review of the literature. Adv Contracept 1992; 8 Suppl. 1: 35-45
34. Archer DF. Menstrual-cycle related symptoms: a review of the rationale for continuous use of oral contraceptives. Contraception 2006; 74: 359-66
35. Proctor M, Farquhar C. Diagnosis and management of dysmenorrhoea. BMJ 2006; 332 (7550): 1134-8 (Pubitemid 44480881)
36. Goppelt-Struebe M, Wolter D, Resch K. Glucocorticoids inhibit prostaglandin synthesis not only at the level of phospholipase A2 but also at the level of cyclo-oxygenase/ PGE isomerase. Br J Pharmacol 1989; 98 (4): 1287-95 (Pubitemid 20011085)
37. Hanjalic-Beck A, Schaüfer WR, Fischer L, et al. Ex vivo and in vitro assays for testing progestogenic effects on endometrial phospholipid-/ arachidonic-acid metabolism [abstract]. Presented at the 8th Congress of the European Society of Gynecology, Rome; 2009 Sep 10-13
38. Zahradnik HP. Progestogen and endometrial regulation: theoretical and clinical considerations [abstract]. Presented at the 13thWorldCongress ofGynecological Endocrinology, Florence; 2008 Feb 28-Mar 2
39. Zahradnik HP. Symposium Grunenthal, Gynovatoins 2008. Monaco 1998; 57 (2): 103-9
40. Sabatini R, Orsini G, Cagniano R, et al. Noncontraceptive benefits of two combined oral contraceptives with antiandrogenic properties among adolescents. Contraception 2007; 76 (5): 342-7 (Pubitemid 47600123)
41. Zahradnik HP, Goldberg J, Andreas JE. Efficacy and safety of new antiandrogenic oral contraceptive Belara-. Contraception 1998; 57 (2): 103-9 (Pubitemid 28208481)
42. Corson SL. Efficacy and clinical profile of a new oral contraceptive containing norgestimate. Acta Obstet Gynecol Scand 1990; 152 Suppl.: 25-31
43. Speroff L, DeCherny A, Advisory board for the new progestin. Evaluation of a new generation of oral contraceptives. Obstet Gynecol 1993; 81: 1034-47
44. Runnebaum B, Rabe T. In:Gynaükologische endokrinologie. Berlin, Heidelberg, New York: Springer, 1994: 412-53